REVENUE RECOGNITION - Schedule of net revenue from collaborative arrangements (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenue Recognition and Collaborative Arrangements
Net revenue	$ 331,339	$ 391,866	$ 336,794
Royalty revenue
Revenue Recognition and Collaborative Arrangements
Less: amortization of capitalized fees paid	(13,823)	(13,823)	(13,823)
Net revenue	311,645	391,866	326,794
Revenue from collaborative arrangements
Revenue Recognition and Collaborative Arrangements
Net revenue	0	0	10,000
GSK
Revenue Recognition and Collaborative Arrangements
Net revenue	311,645	391,866	336,794
GSK | Royalty revenue
Revenue Recognition and Collaborative Arrangements
Royalties	325,468	405,689	340,617
Less: amortization of capitalized fees paid	(13,823)	(13,823)	(13,823)
Net revenue	311,645	391,866	326,794
GSK | RELVAR/BREO
Revenue Recognition and Collaborative Arrangements
Royalties	215,034	234,066	221,536
GSK | ANORO
Revenue Recognition and Collaborative Arrangements
Royalties	38,405	44,935	45,992
GSK | TRELEGY
Revenue Recognition and Collaborative Arrangements
Royalties	72,029	126,688	73,089
GSK | Revenue from collaborative arrangements | Strategic alliance - MABA program
Revenue Recognition and Collaborative Arrangements
Strategic alliance - MABA program	$ 0	$ 0	$ 10,000